NEW YORK --  Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating th…

Financial Post

Canada

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Media Bias/Fact Check

Leon Cooperman

Allianz

LIKE BOING BOING BUT NOT THE ADS?   CLICK HERE TO GO AD-FREE!  Biopharma firm Mind Medicine announced that they have dosed the first-ever patient in a Phase 3 clinical trial of LSD. The individual tripped on lysergide D-tartrate, an LSD formulation for which the US FDA granted "breakthrough therapy" status in March as a promising treatment for generalized anxiety disorder (GAD). — Read the rest  The post The first-ever patient in a Phase 3 medic…

Ad Fontes Media

All Sides

Boing Boing

United States

The first-ever patient in a Phase 3 medical study of LSD has successfully tripped balls

Green Stock News for the New Green Economy.

Green Stock News

Mind Medicine Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized anxiety disorder (GAD). Drugmaker MindMed says that the trial, dubbed Voyage, is eventually expected to enroll about 200 people in the U.S. and will compare the effects of its proprietary LSD product to a placebo. A second Phase 3 trial, called Panorama, …

Marijuana Moment

First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety

newsbudz.com

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized anxiety disorder (GAD). Drugmaker MindMed says that the trial, dubbed Voyage, is eventually expected to enroll about 200 people in the U.S. and The post First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety appeared first on Mari…

Cannabis News World

First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety - Cannabis News World

The Marijuana Herald - Marijuana news and information Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Representative Image of MM120 ODT/Courtesy of Catalent. Voyage is the first o…

The Marijuana Herald

MindMed Launches Phase 3 Trials for LSD-Based Treatment to Tackle Anxiety Disorders, Announces First Patient Dosed

MindMed has dosed the first subject in a Phase III study of MM120 tablets for the treatment of generalised anxiety disorder.The post MindMed doses first subject in trial of tablets for generalised anxiety disorder appeared first on Clinical Trials Arena.

Clinical Trials Arena

MindMed doses first subject in trial of tablets for generalised anxiety disorder

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way!

psychiatrictimes.com

First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder

MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety disorder (GAD). Voyage is the first-ever Phase 3 study of LSD, with the primary endpoint measuring the change from base line in the Hamilton Anxiety Rating Scale score at week 12 for MM120 ODT 100 µg compared to a placebo. The first…

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics